177 related articles for article (PubMed ID: 32987797)
1. Prognostic Significance of Aberrant Claudin-6 Expression in Endometrial Cancer.
Kojima M; Sugimoto K; Tanaka M; Endo Y; Kato H; Honda T; Furukawa S; Nishiyama H; Watanabe T; Soeda S; Fujimori K; Chiba H
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987797
[TBL] [Abstract][Full Text] [Related]
2. Identification of Claudin-6 as a Molecular Biomarker in Pan-Cancer Through Multiple Omics Integrative Analysis.
Zhang C; Guo C; Li Y; Liu K; Zhao Q; Ouyang L
Front Cell Dev Biol; 2021; 9():726656. PubMed ID: 34409042
[TBL] [Abstract][Full Text] [Related]
3. Claudin‑9 is a novel prognostic biomarker for endometrial cancer.
Endo Y; Sugimoto K; Kobayashi M; Kobayashi Y; Kojima M; Furukawa S; Soeda S; Watanabe T; Higashi AY; Higashi T; Hashimoto Y; Fujimori K; Chiba H
Int J Oncol; 2022 Nov; 61(5):. PubMed ID: 36129146
[TBL] [Abstract][Full Text] [Related]
4. The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis.
Simon AG; Lyu SI; Laible M; Wöll S; Türeci Ö; Şahin U; Alakus H; Fahrig L; Zander T; Buettner R; Bruns CJ; Schroeder W; Gebauer F; Quaas A
J Transl Med; 2023 Aug; 21(1):552. PubMed ID: 37592303
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of claudin-6 contributes to malignant potentials and drug resistance of cervical adenocarcinoma.
Ito Y; Takasawa A; Takasawa K; Murakami T; Akimoto T; Kyuno D; Kawata Y; Shano K; Kirisawa K; Ota M; Aoyama T; Murata M; Sugimoto K; Chiba H; Saito T; Osanai M
Cancer Sci; 2022 Apr; 113(4):1519-1530. PubMed ID: 35100472
[TBL] [Abstract][Full Text] [Related]
6. Expression of CLDN6 in tissues of gastric cancer patients: Association with clinical pathology and prognosis.
Gao F; Li M; Xiang R; Zhou X; Zhu L; Zhai Y
Oncol Lett; 2019 May; 17(5):4621-4625. PubMed ID: 30988820
[TBL] [Abstract][Full Text] [Related]
7. Identification of claudin-2, -6, -11 and -14 as prognostic markers in human breast carcinoma.
Jia H; Chai X; Li S; Wu D; Fan Z
Int J Clin Exp Pathol; 2019; 12(6):2195-2204. PubMed ID: 31934042
[TBL] [Abstract][Full Text] [Related]
8. Association of CLDN6 and CLDN10 With Immune Microenvironment in Ovarian Cancer: A Study of the Claudin Family.
Gao P; Peng T; Cao C; Lin S; Wu P; Huang X; Wei J; Xi L; Yang Q; Wu P
Front Genet; 2021; 12():595436. PubMed ID: 34249076
[TBL] [Abstract][Full Text] [Related]
9. Reduced Claudin-12 Expression Predicts Poor Prognosis in Cervical Cancer.
Rahman A; Kobayashi M; Sugimoto K; Endo Y; Kojima M; Furukawa S; Watanabe T; Soeda S; Hashimoto Y; Fujimori K; Chiba H
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33917356
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation of claudin-6 promotes breast cancer cell migration and invasion by recruiting MeCP2 and deacetylating H3Ac and H4Ac.
Liu Y; Jin X; Li Y; Ruan Y; Lu Y; Yang M; Lin D; Song P; Guo Y; Zhao S; Dong B; Xie Y; Dang Q; Quan C
J Exp Clin Cancer Res; 2016 Jul; 35(1):120. PubMed ID: 27461117
[TBL] [Abstract][Full Text] [Related]
11. Claudin 6: Therapeutic prospects for tumours, and mechanisms of expression and regulation (Review).
Du H; Yang X; Fan J; Du X
Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34296304
[TBL] [Abstract][Full Text] [Related]
12. CLDN6 promotes chemoresistance through GSTP1 in human breast cancer.
Yang M; Li Y; Shen X; Ruan Y; Lu Y; Jin X; Song P; Guo Y; Zhang X; Qu H; Shao Y; Quan C
J Exp Clin Cancer Res; 2017 Nov; 36(1):157. PubMed ID: 29116019
[TBL] [Abstract][Full Text] [Related]
13. The Expression of CLDN6 in Hepatocellular Carcinoma Tissue and the Effects of CLDN6 on Biological Phenotypes of Hepatocellular Carcinoma Cells.
Lu Y; Dang Q; Bo Y; Su X; Wang L; Sun J; Wei J; Quan C; Li Y
J Cancer; 2021; 12(18):5454-5463. PubMed ID: 34405008
[TBL] [Abstract][Full Text] [Related]
14. Role of the Cldn6 cytoplasmic tail domain in membrane targeting and epidermal differentiation in vivo.
Arabzadeh A; Troy TC; Turksen K
Mol Cell Biol; 2006 Aug; 26(15):5876-87. PubMed ID: 16847338
[TBL] [Abstract][Full Text] [Related]
15. Antibody specificity against highly conserved membrane protein Claudin 6 driven by single atomic contact point.
Screnci B; Stafford LJ; Barnes T; Shema K; Gilman S; Wright R; Al Absi S; Phillips T; Azuelos C; Slovik K; Murphy P; Harmon DB; Charpentier T; Doranz BJ; Rucker JB; Chambers R
iScience; 2022 Dec; 25(12):105665. PubMed ID: 36505931
[TBL] [Abstract][Full Text] [Related]
16. Isolate-dependent use of claudins for cell entry by hepatitis C virus.
Haid S; Grethe C; Dill MT; Heim M; Kaderali L; Pietschmann T
Hepatology; 2014 Jan; 59(1):24-34. PubMed ID: 23775920
[TBL] [Abstract][Full Text] [Related]
17. CLDN6-induced apoptosis via regulating ASK1-p38/JNK signaling in breast cancer MCF-7 cells.
Guo Y; Lin D; Zhang M; Zhang X; Li Y; Yang R; Lu Y; Jin X; Yang M; Wang M; Zhao S; Quan C
Int J Oncol; 2016 Jun; 48(6):2435-44. PubMed ID: 27035750
[TBL] [Abstract][Full Text] [Related]
18. Up-Regulation of Claudin-6 in the Distal Lung Impacts Secondhand Smoke-Induced Inflammation.
Lewis JB; Milner DC; Lewis AL; Dunaway TM; Egbert KM; Albright SC; Merrell BJ; Monson TD; Broberg DS; Gassman JR; Thomas DB; Arroyo JA; Reynolds PR
Int J Environ Res Public Health; 2016 Oct; 13(10):. PubMed ID: 27763528
[TBL] [Abstract][Full Text] [Related]
19. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
[TBL] [Abstract][Full Text] [Related]
20. Identification of claudin‑1, ‑3, ‑7 and ‑8 as prognostic markers in human laryngeal carcinoma.
Zhou S; Piao X; Wang C; Wang R; Song Z
Mol Med Rep; 2019 Jul; 20(1):393-400. PubMed ID: 31115553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
